Growth hormone replacement and the risk of malignancy in children with neurofibromatosis.

2.50
Hdl Handle:
http://hdl.handle.net/10541/91992
Title:
Growth hormone replacement and the risk of malignancy in children with neurofibromatosis.
Authors:
Howell, Simon J; Wilton, Patrick; Lindberg, Anders; Shalet, Stephen M
Abstract:
OBJECTIVE: To assess the efficacy and safety of growth hormone (GH) therapy in children with GH deficiency in association with neurofibromatosis. METHODS: Retrospective analysis of data from the Pharmacia and Upjohn International Growth Database (KIGS) in a total of 102 GH-deficient children with neurofibromatosis treated with recombinant GH. RESULTS: Median pretreatment height velocity was 4.2 cm/yr (1.7 to 6.4 cm/yr), increased to 7.1 cm/yr (4.6 to 10.0 cm/yr) in the first year of GH therapy, and remained significantly greater than pretreatment at 5.7 cm/yr (2.9 to 8.3 cm/yr) and 5.7 cm/yr (2.6 to 7.9 cm/yr) in the second and third years, respectively. The median height SD score increased from -2.4 to -1.8 by the end of 3 years of treatment. Five patients had either a recurrence of an intracranial tumor or a second intracranial tumor; this incidence of tumor occurrence is comparable to that reported previously in similar patients with neurofibromatosis. Other adverse events were relatively minor and unlikely to be attributable to GH therapy CONCLUSIONS: The data indicate that GH replacement therapy, per se, for patients with neurofibromatosis and GH deficiency is likely to be beneficial and unassociated with excessive malignant risk.
Affiliation:
Department of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom.
Citation:
Growth hormone replacement and the risk of malignancy in children with neurofibromatosis. 1998, 133 (2):201-5 J. Pediatr.
Journal:
Journal of Pediatrics
Issue Date:
Aug-1998
URI:
http://hdl.handle.net/10541/91992
PubMed ID:
9709706
Type:
Article
Language:
en
ISSN:
0022-3476
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Simon Jen
dc.contributor.authorWilton, Patricken
dc.contributor.authorLindberg, Andersen
dc.contributor.authorShalet, Stephen Men
dc.date.accessioned2010-02-12T15:04:40Z-
dc.date.available2010-02-12T15:04:40Z-
dc.date.issued1998-08-
dc.identifier.citationGrowth hormone replacement and the risk of malignancy in children with neurofibromatosis. 1998, 133 (2):201-5 J. Pediatr.en
dc.identifier.issn0022-3476-
dc.identifier.pmid9709706-
dc.identifier.urihttp://hdl.handle.net/10541/91992-
dc.description.abstractOBJECTIVE: To assess the efficacy and safety of growth hormone (GH) therapy in children with GH deficiency in association with neurofibromatosis. METHODS: Retrospective analysis of data from the Pharmacia and Upjohn International Growth Database (KIGS) in a total of 102 GH-deficient children with neurofibromatosis treated with recombinant GH. RESULTS: Median pretreatment height velocity was 4.2 cm/yr (1.7 to 6.4 cm/yr), increased to 7.1 cm/yr (4.6 to 10.0 cm/yr) in the first year of GH therapy, and remained significantly greater than pretreatment at 5.7 cm/yr (2.9 to 8.3 cm/yr) and 5.7 cm/yr (2.6 to 7.9 cm/yr) in the second and third years, respectively. The median height SD score increased from -2.4 to -1.8 by the end of 3 years of treatment. Five patients had either a recurrence of an intracranial tumor or a second intracranial tumor; this incidence of tumor occurrence is comparable to that reported previously in similar patients with neurofibromatosis. Other adverse events were relatively minor and unlikely to be attributable to GH therapy CONCLUSIONS: The data indicate that GH replacement therapy, per se, for patients with neurofibromatosis and GH deficiency is likely to be beneficial and unassociated with excessive malignant risk.en
dc.language.isoenen
dc.subjectBrain Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAdolescent-
dc.subject.meshBody Height-
dc.subject.meshBrain Neoplasms-
dc.subject.meshChild-
dc.subject.meshGrowth Disorders-
dc.subject.meshGrowth Hormone-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeurofibromatoses-
dc.subject.meshRecombinant Proteins-
dc.subject.meshRetrospective Studies-
dc.titleGrowth hormone replacement and the risk of malignancy in children with neurofibromatosis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital NHS Trust, Withington, Manchester, United Kingdom.en
dc.identifier.journalJournal of Pediatricsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.